Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji
Warsaw, Poland5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, juvenile idiopathic arthritis, musculoskeletal system disorder, rheumatic disorder | Recruiting | Phase 3 | 2026-10-07 | NCT03773965 | |
| FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression | interstitial lung disease, lung disorder, respiratory system disorder | Recruiting | Phase 3 | 2026-10-01 | NCT07540988 | |
| Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypogammaglobulinemia, Infections, agammaglobulinemia, hematologic disorder, immune system disorder, inborn error of immunity, lymphatic system disorder, lymphoproliferative syndrome | Recruiting | Phase 3 | 2026-09-29 | NCT07220915 | |
| A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) | Body Temperature Changes, Fever, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, juvenile idiopathic arthritis, musculoskeletal system disorder, rheumatic disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT04088396 | |
| Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, diffuse scleroderma, immune system disorder, interstitial lung disease, lung disorder, respiratory system disorder, scleroderma, skin disorder, systemic sclerosis | Active, not recruiting | Phase 2 | 2026-07-20 | NCT06843239 |